Literature DB >> 12213657

Regulation of transcription elongation by phosphorylation.

Michael S Kobor1, Jack Greenblatt.   

Abstract

The synthesis of mRNA by RNA polymerase II (RNAPII) is a multistep process that is regulated by different mechanisms. One important aspect of transcriptional regulation is phosphorylation of components of the transcription apparatus. The phosphorylation state of RNAPII carboxy-terminal domain (CTD) is controlled by a variety of protein kinases and at least one protein phosphatase. We discuss emerging genetic and biochemical evidence that points to a role of these factors not only in transcription initiation but also in elongation and possibly termination. In addition, we review phosphorylation events involving some of the general transcription factors (GTFs) and other regulatory proteins. As an interesting example, we describe the modulation of transcription associated kinases and phosphatase by the HIV Tat protein. We focus on bringing together recent findings and propose a revised model for the RNAPII phosphorylation cycle.

Mesh:

Substances:

Year:  2002        PMID: 12213657     DOI: 10.1016/s0167-4781(02)00457-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  74 in total

1.  The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA.

Authors:  Meisheng Zhou; Longwen Deng; Fatah Kashanchi; John N Brady; Aaron J Shatkin; Ajit Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

2.  A 10 residue motif at the C-terminus of the RNA pol II CTD is required for transcription, splicing and 3' end processing.

Authors:  Nova Fong; Gregory Bird; Marc Vigneron; David L Bentley
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

3.  RNA polymerase II carboxy-terminal domain phosphorylation is required for cotranscriptional pre-mRNA splicing and 3'-end formation.

Authors:  Gregory Bird; Diego A R Zorio; David L Bentley
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

Review 4.  Cancer models in Caenorhabditis elegans.

Authors:  Natalia V Kirienko; Kumaran Mani; David S Fay
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

5.  Interaction of Bunyamwera Orthobunyavirus NSs protein with mediator protein MED8: a mechanism for inhibiting the interferon response.

Authors:  Vincent H J Léonard; Alain Kohl; Timothy J Hart; Richard M Elliott
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

6.  Interaction between human respiratory syncytial virus (RSV) M2-1 and P proteins is required for reconstitution of M2-1-dependent RSV minigenome activity.

Authors:  Stephen W Mason; Erika Aberg; Carol Lawetz; Rachel DeLong; Paul Whitehead; Michel Liuzzi
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Herpes simplex virus type 1 infection leads to loss of serine-2 phosphorylation on the carboxyl-terminal domain of RNA polymerase II.

Authors:  Kathryn A Fraser; Stephen A Rice
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  NF-kappaB-repressing factor inhibits elongation of human immunodeficiency virus type 1 transcription by DRB sensitivity-inducing factor.

Authors:  Ursula Dreikhausen; Kirsten Hiebenthal-Millow; Myriam Bartels; Klaus Resch; Mahtab Nourbakhsh
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  The histone 3 lysine 36 methyltransferase, SET2, is involved in transcriptional elongation.

Authors:  Daniel Schaft; Assen Roguev; Kimberly M Kotovic; Anna Shevchenko; Mihail Sarov; Andrej Shevchenko; Karla M Neugebauer; A Francis Stewart
Journal:  Nucleic Acids Res       Date:  2003-05-15       Impact factor: 16.971

10.  Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.

Authors:  Hiroshi Hirai; Ikuko Takahashi-Suziki; Toshiyasu Shimomura; Kazuhiro Fukasawa; Takumitsu Machida; Toru Takaki; Makiko Kobayashi; Tomohiro Eguchi; Hiroko Oki; Tsuyoshi Arai; Koji Ichikawa; Shinichi Hasako; Tsutomu Kodera; Nobuhiko Kawanishi; Yoko Nakatsuru; Hidehito Kotani; Yoshikazu Iwasawa
Journal:  Invest New Drugs       Date:  2010-01-19       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.